Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.

A pharmaceutical combination comprising a compound represented by formula (I) or its pharmaceutically acceptable salt,

• Wherein;
• R1 is —R4—R5 or —N(R7)N(R7)R9;
• R4 is selected from the group consisting of —N(R7)R6O—, —N (R7)R6N(R7)—, OR6O,
• and —OR6N(R7)—, where R6 is alkyl with C2 to C8 carbon atoms;
• R5 is selected from the group consisting of alkyl, aryl including heteroaryl, —CORS, SO2R7, —C(S)NHR7, —C(NH)NHR7, —COR10,
• where R7 is selected from the group consisting of H, alkyl and aryl including heteroaryl provided R7 may be the same or different for R1 and R3 in the same compound;
• R2 is selected from the group consisting of F, Cl, Br, I, OR7, NO2, alkyl, aryl including heteroaryl, formyl, acyl, C(O)NR7R10, C(O)OR7, NR7R10, N═C(R7)(R10), SR7, SO2NH2, SO2 alkyl and SO2aryl,
• and m is 0, 1 or 2;
• R3 is selected from the group consisting of R7, OR7, N(R7)(R10), N═C(R7)(R10), N(R7)N(R7)(R10), N(R7)N═C(R7)(R10) and CH(R7)C(O)R8;
• where R8 is selected from the group consisting of R7, OR7 and NR7R10;
• R9 is selected from the group consisting of hydrogen, alkyl, aryl including heteroaryl, C(O)R10, —SO2R10, —C(S)NHR10, —C(NH)NH(R10) and —C(O)NHR10,
• R10 is selected for the group consisting of H, alkyl or aryl including heteroaryl and in each case may be the same or different from substituent R7, provided R10 may be the same or different for R1 and R3 in the same compound;
• X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF4− and PF6− or null;
• with proviso that,
• (i) when two alkyl groups are present on the same carbon or nitrogen, they may be linked together to form a cyclic structure;
• (ii) the nitrogen of heteroaryl ring of R10, when present, may be quaternized;
• (iii) when R3 is OR7 and R1 is —NHNH2 then R7 is not alkyl and
• (iv) when R3 is OR7, R1 is N(R7)(NR7)R9 and R9 is C(O)R10 where R10 is alkyl, then R7 is not hydrogen.
• and/or a compound represented by formula (II) or its pharmaceutically acceptable salt thereof,
• wherein,
• R1 is alkyl or aryl group;
• Y is selected from the group comprising of sulfur, oxygen, nitrogen, or alkylene;
• A and B are independently selected from nitrogen, NH, NR6, sulfur, oxygen or carbon to form heteroaromatic ring system;
• R2, R3 and R4 are independently selected from the group consisting of F, Cl, Br, I, OR7, NO2, alkyl, aryl including heteroaryl, formyl, acyl, C(O)NR6R7, C(O)OR6, NR6R7, N═C(R6)(R7), SR6, SO2NH2, SO2alkyl, SO2aryl;
• R2, R3 and R4 might be optionally joined together to form a ring system;
• R5 is independently selected for the group consisting of alkyl, aryl and null;
• R6 is independently selected from the group consisting of H, alkyl and aryl including heteroaryl provided R6 might be different for R2, R3 and R4 in the same compound;
• R7 is independently selected from the group consisting of H, alkyl and aryl including heteroaryl and in each case optionally different from substituent R6, provided R7 might be different for R2, R3 and R4 in the same compound;
• X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogenion;
• phosphonate ion, phosphate ion, BF4, PF6 and null;
• with proviso that when two alkyl groups are present on the same carbon or nitrogen, they are optionally linked together to form a cyclic structure;
• and at least one therapeutic agent selected from the group consisting of:
• a) antihypertensive agent;
• b) hypolipemic agent;
• c) antidiabetic agent;
• d) antiplatelet agent;
• e) anti-thrombotic agent;
• f) antiobesity agent;
• g) agent for treatment of heart failure;
• and h) drug for diabetic vascular complications;
• or a pharmaceutically acceptable salts thereof.